Dyno Therapeutics is a Cambridge based, VC-backed biotech startup that uses next-gen DNA technologies and machine learning to engineer Adeno-associated Virus (AAV) capsids for effective delivery of gene therapies.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $109M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | KdT Ventur... | kdtvc.com |
| 08.05.2021 | Lux Capita... | luxcapital... |
| - | Sahsen Ven... | sahsen.com |
| 12.05.2021 | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.05.2021 | Series A | $100M | - |
| 11.05.2020 | Seed | $9M | - |
Mentions in press and media 10
| Date | Title | Description |
| 18.08.2026 | The startup using AI to help rare disease families develop custom treatments | Nome is building an AI-powered drug development service for ultra-rare disease patients, helping families identify potential treatments and map out a path from diagnosis to clinical development. The startup targets patient groups often over... |
| 28.11.2025 | ZAKA VC Backs Nephrogen’s Kidney-Focused Gene Therapy Platform | ZAKA VC supports Nephrogen, a gene therapy startup for kidney and pancreas diseases The founder is motivated by personal health experience to develop a cure Nephrogen’s NeFIND™ platform enables precise, efficient, and scalable gene therapy ... |
| 22.05.2023 | Dyno Therapeutics Launches the Dyno bCap 1 Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence | – Dyno bCap 1 exhibits 100x improvement versus AAV9 in delivery to the central nervous system (CNS) and 10x detargeting of liver after intravenous (IV) dosing, as characterized across multiple non-human primate (NHP) species – – Compared he... |
| 07.05.2021 | Dyno Therapeutics gets $100M in a16z-led round | Dyno Therapeutics, a biotech startup that's applying AI to gene therapy, has announced a $100 million Series A led by Andreessen Horowitz, with participation from new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital.... |
| 06.05.2021 | Dyno grabs $100M to expand tech, build team, ink more gene therapy partnerships | Dyno Therapeutics emerged last year with a modest seed round and Big Pharma partnerships to fuel its work designing new and improved viral vectors to deliver gene therapy. Now, the company is kicking it up a notch with a $100 million financ... |
| 06.05.2021 | Dyno Therapeutics Closes $100M Series A Financing | Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing. The round was led by Andreessen Horowitz, with participation from a select sy... |
| 06.05.2021 | Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI‑powered Gene Therapy Platform | Dyno Therapeutics, Inc., a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investor... |
| 19.10.2020 | AI drug-discovery firm lands first partnership | Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 11.05.2020 | Dyno Therapeutics Raises $9M in Seed Financing | Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $9m in not previously announced seed financing round. The round – secured when Dyno spun out of the lab of... |
| - | AI drug-discovery firm lands first partnership | Roche Group subsidiary Genentech has tapped a startup drug-discovery firm to find potential drug candidates for a variety of diseases. The deal with Genesis Therapeutics includes an upfront payment and a series of milestone payments as well... |